Login / Signup

Subsequent anti-myeloma therapy after maturation antigen (BCMA) chimeric antigen receptor (CAR)-T cell (HDS269B) treatment in patients with relapsed/refractory multiple myeloma.

Dongjian ChenXiaoxiang WangZhi ChengSongfu JiangHua JiangWeijun FuFang XiangXuedong SunJuan Du
Published in: American journal of hematology (2022)
Keyphrases
  • multiple myeloma
  • acute lymphoblastic leukemia
  • acute myeloid leukemia
  • diffuse large b cell lymphoma
  • stem cells
  • combination therapy
  • replacement therapy